Your request to link to rcsb for Tyrosine-protein kinase BTK

---

• 1K2P: crystal structure of bruton's tyrosine kinase domain (10.1074/JBC.M104828200 )
• 1QLY: nmr study of the sh3 domain from bruton's tyrosine kinase, 20 structures (10.1023/A:1008376624863 )
• 2GE9: solution structures of the sh2 domain of bruton's tyrosine kinase (10.1007/S10858-006-9064-3 )
• 2Z0P: crystal structure of ph domain of bruton's tyrosine kinase (10.1016/J.BBRC.2008.09.055 )
• 3GEN: the 1.6 a crystal structure of human bruton's tyrosine kinase bound to a pyrrolopyrimidine-containing compound (10.1002/PRO.321 )
• 3K54: structures of human bruton's tyrosine kinase in active and inactive conformations suggests a mechanism of activation for tec family kinases. (10.1002/PRO.321 )
• 3OCS: crystal structure of bruton's tyrosine kinase in complex with inhibitor cgi1746
• 3OCT: crystal structure of bruton's tyrosine kinase mutant v555r in complex with dasatinib
• 3P08: crystal structure of the human btk kinase domain
• 3PIX: crystal structure of btk kinase domain complexed with 2-isopropyl-7- (4-methyl-piperazin-1-yl)-4-(5-methyl-2h-pyrazol-3-ylamino)-2h- phthalazin-1-one (10.1002/PRO.575 )
• 3PIY: crystal structure of btk kinase domain complexed with r406 (10.1002/PRO.575 )
• 3PIZ: crystal structure of btk kinase domain complexed with (5-amino-1-o- tolyl-1h-pyrazol-4-yl)-[3-(1-methanesulfonyl-piperidin-4-yl)-phenyl]- methanone (10.1002/PRO.575 )
• 3PJ1: crystal structure of btk kinase domain complexed with 3-(2,6-dichloro- phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]-1-methyl-3,4- dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one (10.1002/PRO.575 )
• 3PJ2: crystal structure of btk kinase domain complexed with 2-[4-(2- diethylamino-ethoxy)-phenylamino]-6-(4-fluoro-phenoxy)-8-methyl-8h- pyrido[2,3-d]pyrimidin-7-one (10.1002/PRO.575 )
• 3PJ3: crystal structure of btk kinase domain complexed with 2-methyl-5-[(e)- (3-phenyl-acryloyl)amino]-n-(2-phenyl-3h-imidazo[4,5-b]pyridin-6-yl)- benzamide (10.1002/PRO.575 )
• 4NWM: crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with bms-809959 aka 4-tert-butyl-n-[2-me thyl-3-(6-{[4- (morpholine-4-carbonyl)phenyl]amino}-9h- purin-2-yl)phenyl]benzamide (10.1016/J.BMCL.2014.02.075 )
• 4OT5: crystal structure of btk kinase domain complexed with 4-tert-butyl-n- (3-{8-[4-(4-methyl-piperazine-1-carbonyl)-phenylamino]-imidazo[1,2- a]pyrazin-6-yl}-phenyl)-benzamide (10.1021/JM500305P )
• 4OT6: crystal structure of btk kinase domain complexed with 4- methanesulfonyl-n-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]- imidazo[1,2-a]pyrazin-6-yl}-phenyl)-benzamide (10.1021/JM500305P )
• 4OTF: crystal structure of the kinase domain of bruton's tyrosine kinase with gdc0834 (10.1016/J.BMCL.2015.01.032 )
• 4OTQ: crystal structure of btk kinase domain complexed with 1-[5-[3-(7-tert- butyl-4-oxo-quinazolin-3-yl)-2-methyl-phenyl]-1-methyl-2-oxo-3- pyridyl]-3-methyl-urea (10.1021/JM500305P )
• 4OTR: crystal structure of btk kinase domain complexed with 6-cyclopropyl-2- [3-[5-[[5-(4-ethylpiperazin-1-yl)-2-pyridyl]amino]-1-methyl-6-oxo-3- pyridyl]-2-(hydroxymethyl)phenyl]-8-fluoro-isoquinolin-1-one (10.1021/JM500305P )
• 4RFY: crystal structure of btk kinase domain complexed with 6- (dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4- carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4- dihydroisoquinolin-1-one (10.1016/J.BMCL.2014.11.030 )
• 4RFZ: crystal structure of btk kinase domain complexed with 6- (dimethylamino)-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5- (morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3- pyridyl]phenyl]isoquinolin-1-one (10.1016/J.BMCL.2014.11.030 )
• 4RG0: crystal structure of btk kinase domain complexed with 2-[8-fluoro-2- [2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)-2- pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-1-oxo-3,4-dihydroisoquinolin- 6-yl]-2-methyl-propanenitrile (10.1016/J.BMCL.2014.11.030 )
• 4RX5: bruton's tyrosine kinase (btk) with pyridazinone compound 23 (10.1016/J.BMCL.2015.11.076 )
• 4XI2: crystal structure of an auto-inhibited form of bruton's tryrosine kinase (10.7554/ELIFE.06074 )
• 4Y93: crystal structure of the ph-th-kinase construct of bruton's tyrosine kinase (btk) (10.7554/ELIFE.06074 )
• 4Y94: crystal structure of the ph-th module of bruton's tyrosine kinase bound to inositol hexakisphosphate (10.7554/ELIFE.06074 )
• 4Y95: crystal structure of the kinase domain of bruton's tyrosine kinase with mutations in the activation loop (10.7554/ELIFE.06074 )
• 4YHF: bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor (10.1038/NCHEMBIO.1817 )
• 4Z3V: fragment-based discovery of a small molecule reversible inhibitor of bruton's tyrosine kinase (10.1021/ACS.JMEDCHEM.5B00734 )
• 4ZLY: crystal structure of bruton's tyrosine kinase bound to a cinnoline fragment (10.1021/ACS.JMEDCHEM.5B00734 )
• 4ZLZ: crystal structure of bruton's tyrosine kinase in complex with a substituted cinnoline (10.1021/ACS.JMEDCHEM.5B00734 )
• 5BPY: crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with bms-824171 aka 6-[(3r)-3-(4-tert-bu tylbenzamido) piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine- 3-carboxamide (10.1016/J.BMCL.2015.07.102 )
• 5BQ0: crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with bms-824171 aka 6-[(3r)-3-(4-tert-bu tylbenzamido) piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine- 3-carboxamide (10.1016/J.BMCL.2015.07.102 )
• 5FBN: btk kinase domain with inhibitor 1 (10.1021/ACSMEDCHEMLETT.5B00463 )
• 5FBO: btk-inhibitor co-structure (10.1021/ACSMEDCHEMLETT.5B00463 )
• 5J87: discovery of n-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl) amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4- (tert-butyl)benzamide (chmfl-btk-01) as a highly selective irreversible btk kinase inhibitor (10.1016/J.EJMECH.2017.03.001 )
• 5JRS: crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with 4-[2-fluoro-3-(4-oxo -3,4-dihydroquinazolin-3-yl) phenyl]-7-(2-hydroxypropan-2-y l)-9h-carbazole-1-carboxamide (10.1021/ACS.JMEDCHEM.6B00722 )
• 5KUP: bruton's tyrosine kinase (btk) with pyridazinone compound 9 (10.1021/ACSCHEMBIO.6B00480 )
• 5P9F: btk in complex with gdc-0834 (10.1124/MOL.116.107037 )
• 5P9G: structure of btk with rn486 (10.1124/MOL.116.107037 )
• 5P9H: btk1 cocrystallized with rn983 (10.1124/MOL.116.107037 )
• 5P9I: btk1 soaked with ibrutinib-rev (10.1124/MOL.116.107037 )
• 5P9J: btk1 cocrystallized with ibrutinib (10.1124/MOL.116.107037 )
• 5P9K: crystal structure of btk with cnx 774 (10.1124/MOL.116.107037 )
• 5P9L: btk1 in complex with cc 292 (10.1124/MOL.116.107037 )
• 5P9M: btk1 binds covalently to hy-15771 ono-4059 (10.1124/MOL.116.107037 )
• 5T18: crystal structure of bruton agammabulinemia tyrosine kinase complexed with bms-986142 aka (2s)-6-fluoro-5-[3-(8-fluoro-1-methyl-2,4-dioxo- 1,2,3,4-tetrahydroquinazolin-3-yl)-2-methylphenyl]-2-(2- hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1h-carbazole-8-carboxamide (10.1021/ACS.JMEDCHEM.6B01088 )
• 5U9D: discovery of a potent btk inhibitor with a novel binding mode using parallel selections with a dna-encoded chemical library (10.1002/CBIC.201600573 )
• 5VFI: bruton's tyrosine kinase (btk) with gdc-0853 (10.1021/ACS.JMEDCHEM.7B01712 )
• 5VGO: bruton's tyrosine kinase (btk) with compound g-744 (10.1021/ACSMEDCHEMLETT.7B00103 )
• 5XYZ: the structure of human btk kinase domain in complex with a covalent inhibitor (10.1021/ACS.JMEDCHEM.7B01075 )
• 5ZZ4: crystal structure of bruton's tyrosine kinase in complex with inhibitor 2e (10.1021/ACS.JMEDCHEM.8B01147 )
• 6AUA: crystal structure of bruton's tyrosine kinase in complex with inhibitor cgi2625
• 6AUB: crystal structure of bruton's tyrosine kinase in complex with inhibitor cgi2815
• 6BIK: btk complex with compound 7 (10.1007/S10822-019-00187-Y )
• 6BKE: btk complex with compound 10 (10.1007/S10822-019-00187-Y )
• 6BKH: btk complex with compound 11 (10.1007/S10822-019-00187-Y )
• 6BKW: btk complex with compound 12 (10.1007/S10822-019-00187-Y )
• 6BLN: btk complex with compound 13 (10.1007/S10822-019-00187-Y )
• 6DI0: crystal structure of btk in complex with fragment ligand (10.1016/J.BMCL.2018.09.033 )
• 6DI1: crystal structure of btk in complex with covalent fragment ligand (10.1016/J.BMCL.2018.09.033 )
• 6DI3: crystal structure of btk in complex with fragment ligand (10.1016/J.BMCL.2018.07.008 )
• 6DI5: crystal structure of btk in complex with covalent inhibitor (10.1016/J.BMCL.2018.07.008 )
• 6DI9: crystal structure of btk in complex with covalent inhibitor (10.1016/J.BMCL.2018.07.008 )
• 6E4F: crystal structure of arq 531 in complex with the kinase domain of btk (10.1158/2159-8290.CD-17-1409 )
• 6EP9: crystal structure of btk kinase domain complexed with n-[2-methyl-3- [4-methyl-6-[4-(4-methylpiperazine-1-carbonyl)anilino]-5-oxo-pyrazin- 2-yl]phenyl]-4-(1-piperidyl)benzamide (10.1007/S10822-019-00187-Y )
• 6HRP: crystal structure of btk kinase domain complexed with 6- (dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4- carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4- dihydroisoquinolin-1-one (10.1016/J.BMCL.2019.03.001 )
• 6HRT: crystal structure of btk kinase domain complexed with 12-(6-tert- butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5- (morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02, 7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one (10.1016/J.BMCL.2019.03.001 )
• 6HTF: crystal structure of human btk sh2 domain bound to rf10 repebody (10.1038/S41467-020-16128-5 )
• 6J6M: co-crystal structure of btk kinase domain with zanubrutinib (10.1021/ACS.JMEDCHEM.9B00687 )
• 6MNY: crystal structure of mouse btk kinase domain in complex with compound 9a (10.1021/ACSMEDCHEMLETT.8B00461 )
• 6N9P: discovery of affinity-based probes for btk occupancy assay (10.1002/CMDC.201800714 )
• 6NFH: btk in complex with inhibitor 8-(2,3-dihydro-1h-inden-5-yl)-2-({4- [(2s)-3-(dimethylamino)-2-hydroxypropoxy]phenyl}amino)-5,8- dihydropteridine-6,7-dione (10.1021/ACS.JCIM.8B00941 )
• 6NFI: btk in complex with inhibitor n-(3-{[(2,6-dimethylphenyl) methyl]amino}-7-methoxyindeno[1,2-c]pyrazol-6-yl)methanesulfonamide (10.1021/ACS.JCIM.8B00941 )
• 6NZM: brutons tyrosine kinase in complex with compound 50. (10.1016/J.BMC.2019.05.021 )
• 6O8I: btk in complex with inhibitor (10.1021/ACS.JMEDCHEM.9B00167 )
• 6OMU: structure of human bruton's tyrosine kinase in complex with evobrutinib (10.1021/ACS.JMEDCHEM.9B00794 )
• 6S90: btk in complex with an inhibitor (10.1021/ACSMEDCHEMLETT.9B00317 )
• 6TFP: btk in complex with lou064, a potent and highly selective covalent inhibitor (10.1021/ACS.JMEDCHEM.9B01916 )
• 6TSE: crystal structure of 1-methylindoline-2,3-dione covalently bound to the ph domain of bruton's tyrosine kinase mutant r28c
• 6TT2: the ph domain of bruton's tyrosine kinase mutant r28c
• 6TUH: the ph domain of bruton's tyrosine kinase mutant r28c
• 6TVN: crystal structure of 5-bromoindoline-2,3-dione covalently bound to the ph domain of bruton's tyrosine kinase
• 6VXQ: bruton's tyrosine kinase in complex with compound 5 (10.1021/ACS.JMEDCHEM.0C00702 )
• 6W06: bruton's tyrosine kinase in complex with compound 6 (10.1021/ACS.JMEDCHEM.0C00702 )
• 6W07: bruton's tyrosine kinase in complex with compound 1 (10.1021/ACS.JMEDCHEM.0C00702 )
• 6W7O: ternary complex structure - btk ciap compound 17
• 6W8I: ternary complex structure - btk ciap compound 15
• 6X3N: co-structure of btk kinase domain with l-005085737 inhibitor (10.1016/J.BMCL.2020.127390 )
• 6X3O: co-structure of btk kinase domain with l-005191930 inhibitor (10.1016/J.BMCL.2020.127390 )
• 6X3P: co-structure of btk kinase domain with l-005298385 inhibitor (10.1016/J.BMCL.2020.127390 )
• 6XE4: btk fluorocyclopropyl amide inhibitor, compound 25 (10.1021/ACSMEDCHEMLETT.0C00249 )
• 6YYF: crystal structure of 5-chloroindoline-2,3-dione covalently bound to the ph domain of bruton's tyrosine kinase mutant r28c
• 6YYG: crystal structure of 5-(trifluoromethoxy)indoline-2,3-dione covalently bound to the ph domain of bruton's tyrosine kinase mutant r28c
• 6YYK: crystal structure of 1,5-dimethylindoline-2,3-dione covalently bound to the ph domain of bruton's tyrosine kinase mutant r28c
• 7KXL: btk1 soaked with compound 5, y551 is sequestered (10.1016/J.BMC.2021.116163 )
• 7KXM: btk1 soaked with compound 5, y551 is sequestered (10.1016/J.BMC.2021.116163 )
• 7KXN: btk1 soaked with compound 26 (10.1016/J.BMC.2021.116163 )
• 7KXO: btk1 soaked with compound 24 (10.1016/J.BMC.2021.116163 )
• 7KXP: btk1 soaked with compound 25 (10.1016/J.BMC.2021.116163 )
• 7KXQ: btk1 soaked with compound 30 (10.1016/J.BMC.2021.116163 )
• 7N5O: fragment-based discovery of a novel bruton's tyrosine kinase inhibitor (10.1021/ACS.JMEDCHEM.1C01026 )
• 7N5R: fragment-based discovery of a novel bruton's tyrosine kinase inhibitor (10.1021/ACS.JMEDCHEM.1C01026 )
• 7N5X: fragment-based discovery of a novel bruton's tyrosine kinase inhibitor (10.1021/ACS.JMEDCHEM.1C01026 )
• 7N5Y: fragment-based drug design of a novel, covalent bruton's tyrosine kinase inhibitor (10.1021/ACS.JMEDCHEM.1C01026 )
• 7R60: btk in complex with 18a (10.1002/CMDC.202100453 )
• 7R61: btk in complex with 25a (10.1002/CMDC.202100453 )